Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic Medications
| Autor: | Elayna Rubens, Christoph U. Correll, Nasreen Abdulhamid, Fiju Koshy, Peter Manu, Robert Saint-Vil, Elisse Kramer-Ginsberg, John M. Kane, David Straker |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Blood Glucose Male Psychosis medicine.medical_specialty Adolescent medicine.drug_class Cost-Benefit Analysis medicine.medical_treatment Atypical antipsychotic Internal medicine Prevalence medicine Humans Mass Screening Obesity Antipsychotic Adverse effect Aged Metabolic Syndrome Anthropometry business.industry Mental Disorders Middle Aged medicine.disease Hospitalization Psychiatry and Mental health Blood pressure Endocrinology Hyperglycemia Female Metabolic syndrome business Body mass index Antipsychotic Agents |
| Zdroj: | American Journal of Psychiatry. 162:1217-1221 |
| ISSN: | 1535-7228 0002-953X |
| DOI: | 10.1176/appi.ajp.162.6.1217 |
| Popis: | Despite concerns about the adverse effects of second-generation antipsychotics on weight regulation and glucose and lipid metabolism, little is known about the relationship between these agents and the metabolic syndrome. Because the metabolic syndrome is more strongly associated with cardiovascular morbidity and mortality than its individual components, attention to the full syndrome is important. The authors' goal was to explore the relationship between second-generation antipsychotics and the metabolic syndrome.They assessed the prevalence of metabolic syndrome in a nearly consecutive group of 89 acutely admitted psychiatric inpatients treated with at least one second-generation antipsychotic for different psychiatric disorders. Patients' waist circumference and blood pressure were measured as well as their fasting blood glucose and lipid levels.Twenty-six (29.2%) of the 89 patients fulfilled criteria for the metabolic syndrome. Presence of the syndrome was associated with older age, higher body mass index, and higher values for each individual criterion of the metabolic syndrome but not with specific diagnoses or antipsychotic treatment regimens. Presence of abdominal obesity was most sensitive (92.0%), while fasting glucose110 mg/dl was most specific (95.2%) in correctly identifying the presence of metabolic syndrome. Combining abdominal obesity and elevated fasting blood glucose had 100% sensitivity.The measurement of both abdominal obesity and fasting blood glucose is a simple, cost-effective screening test to detect patients at high risk for future cardiovascular morbidity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|